Literature DB >> 6350167

Suppressive B-cell factor (SBF) produced by FcR-bearing B cells; suppression of B, but not non-B-cell proliferation.

T Suzuki, M Miyama-Inaba, T Masuda, H Uchino, A Murakami, H Tanaka.   

Abstract

B cells that have receptors for the Fc portion of IgG (FcR gamma + B cell) elaborate an immunoregulatory lymphokine termed suppressive B-cell factor (SBF) after binding immune complexes, such as sheep erythrocytes sensitized with IgG anti-sheep erythrocyte antibody (EA). For producing SBF, de novo protein is required, but not DNA or DNA-dependent RNA synthesis. This mediator is released into the culture supernatant of FcR gamma + B cells during 6 to 48 hr after stimulation by EA. SBF suppresses the proliferation of B, but not non-B cells. Thus, it suppressed (i) plaque-forming cell responses in the induction phase in an antigen-non-specific manner, (ii) DNA synthesis of lipopolysaccharide-activated B cells, but neither concanavalin A nor phytohaemagglutinin-activated T cells, and (iii) the proliferation of B but not non-B tumour-cell lines by acting at the G1-S junction in the cell cycle. Concordance of H-2 haplotype between SBF-producing mice and target B cells is necessary for the suppression. Thus, the action of SBF is B-cell specific and antigen-non-specific. Immune complex-mediated negative feedback regulation seems to be operated by lymphokines such as SBF which may be also involved in the surveillance for B-cell tumours.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6350167      PMCID: PMC1454228     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen-antibody complexes.

Authors:  H Rothberger; T S Zimmerman; H L Spiegelberg; J H Vaughan
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

2.  Regulation of fibroblast cell cycle by serum.

Authors:  R F Brooks
Journal:  Nature       Date:  1976-03-18       Impact factor: 49.962

3.  Direct blockade of antigen-reactive B lymphocytes by immune complexes. An 'off' signal for precursors of IgM-producing cells provided by the linkage of antigen-and Fc-receptors.

Authors:  J Oberbarnscheidt; E Kölsch
Journal:  Immunology       Date:  1978-07       Impact factor: 7.397

4.  In vitro studies of immunologically induced secretion of mediators from cells and related phenomena.

Authors:  E L Becker; P M Henson
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

Review 5.  Regulatory effect of antibody on the immune response.

Authors:  J W Uhr; G Möller
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

Review 6.  Inhibition of B lymphocyte activation by interaction with Fc receptors.

Authors:  J L Ryan; P A Henkart
Journal:  Immunol Commun       Date:  1976

7.  The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression.

Authors:  E L Morgan; C H Tempelis
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

8.  The influence of antibodies on immunologic responses. I. The effect on the response to particulate antigen in the rabbit.

Authors:  D S Pearlman
Journal:  J Exp Med       Date:  1967-07-01       Impact factor: 14.307

9.  Competition of 19S and 7S antigen receptors in the regulation of the primary immune response.

Authors:  C Henry; N K Jerne
Journal:  J Exp Med       Date:  1968-07-01       Impact factor: 14.307

10.  B-lymphocytes activation by the Fc region of IgG.

Authors:  M A Berman; W O Weigle
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

View more
  4 in total

1.  Extra mouse mammary tumor proviruses in DBA/2 mouse lymphomas acquire a selective advantage in lymphocytes by alteration in the U3 region of the long terminal repeat.

Authors:  S Yanagawa; A Murakami; H Tanaka
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

2.  A novel lymphokine derived from human IgG Fc receptor-bearing B cells: its suppressive effect on activated T and B lymphocytes including tumour cells in vitro.

Authors:  T Suzuki; Y H Park; M Miyama-Inaba; T Masuda; H Saji; I Nagata; H Uchino
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

3.  Monoclonal SBF produced by a hybridoma: in-vitro and in-vivo suppression of B tumour-cell proliferation.

Authors:  T Suzuki; M Miyama-Inaba; T Masuda; H Uchino; K Ishii
Journal:  Immunology       Date:  1983-12       Impact factor: 7.397

4.  Inhibitory mechanism of the proliferative responses of resting B cells: feedback regulation by a lymphokine (suppressive B-cell factor) produced by Fc receptor-stimulated B cells.

Authors:  T Ohno; M Miyama-Inaba; T Masuda; K Fukuma; K Ajisaka; R Suzuki; K Kumagai; T Kanoh; H Uchino
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.